title: Effect of recombinant human endostatin on the expression of c-Myc and bFGF in mouse gastric cancer cells.
abstract: The aim of this study was to observe the effects of re-combinant human endostatin on the proliferation and apoptosis of mouse gastric cancer cells, and explore some possible mechanisms of recom-binant human endostatin inhibition of cancer. A murine gastric cancer xenograft model was established. A total of 20 mice were divided into two groups (control and experimental groups). The expression of c-Myc and basic fibroblast growth factor (bFGF) was determined by reverse transcription-polymerase chain reaction, Western blotting, and immu-nohistochemical staining methods. Tumor volume was measured and a growth curve was calculated. The tumor diameter in the experimental group was significantly smaller than that in the control group after treat-ment with endostatin for 21 days. The expression levels of c-Myc and bFGF in the experimental group were significantly lower than those of the control group (P < 0.05). There was a positive correlation between the expression of c-Myc and bFGF in the experimental group. Microvessel density was significantly inhibited in the experimental group (P < 0.05). These results demonstrated that recombinant human endostatin could in-hibit tumor metastasis by inhibition of the expression of c-Myc and bFGF in gastric cancer tissue as well as by inhibition of angiogenesis.
authors.affiliation: Department of Radiotherapy, Handan Central Hospital, Affiliated Hospital of Hebei Medical University, Handan, Hebei, China.
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Guo
authors.affiliation: Department of Radiotherapy, Handan Central Hospital, Affiliated Hospital of Hebei Medical University, Handan, Hebei, China yaogendong@sina.com.
authors.forename: G D
authors.initials: GD
authors.lastname: Yao
authors.affiliation: Department of Radiotherapy, Handan Central Hospital, Affiliated Hospital of Hebei Medical University, Handan, Hebei, China.
authors.forename: L P
authors.initials: LP
authors.lastname: Fu
authors.affiliation: Department of Radiotherapy, Handan Central Hospital, Affiliated Hospital of Hebei Medical University, Handan, Hebei, China.
authors.forename: Z G
authors.initials: ZG
authors.lastname: Fu
authors.affiliation: Department of Radiotherapy, Handan Central Hospital, Affiliated Hospital of Hebei Medical University, Handan, Hebei, China.
authors.forename: B
authors.initials: B
authors.lastname: Hou
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D043169:Endostatins / Q000008:administration & dosage* / Q000235:genetics; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000235:genetics; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
chemical_list: D043169:Endostatins; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2